title: The inclusion of fluoxetine into gamma-cyclodextrin increases its bioavailability: behavioral, electrophysiological and pharmacokinetic studies.
abstract: The inclusion of a drug into cyclodextrin generally results in the modification of its physical and chemical properties and sometimes can increase its oral bioavailability. The aim of this study was to compare the effects of the fluoxetine HCl/gamma-cyclodextrin complex to that of traditional fluoxetine HCl. In the forced swimming test in mice, fluoxetine HCl/gamma-cyclodextrin was more effective than fluoxetine HCl, the ED30s being, respectively, 9.5 and 16.9 mg/kg PO. Both compounds (10 mg/kg PO) were able to reduce the firing rate of dorsal raphe neurons in the rat. However, between-groups comparisons showed no significant differences between fluoxetine HCl treated animals and the vehicle group, while fluoxetine HCl/gamma-cyclodextrin appeared significantly more effective than vehicle from minute 25 of the measurement period. In healthy volunteers, the relative oral bioavailability, calculated as the ratio AUC 0-infinity fluoxetine HCl/gamma-cyclodextrin on AUC 0-infinity fluoxetine HCl (20 mg PO), was equal to 249.9%. The three experiments taken together suggest that the complexation of fluoxetine HCl into gamma-cyclodextrin increases its pharmacological efficacy in animals, this effect being related to an enhancement of its oral bioavailability as demonstrated in human healthy subjects.
authors.affiliation: Therabel Research s.a., Brussels, Belgium. infos@research.therabel.com
authors.forename: J
authors.initials: J
authors.lastname: Géczy
authors.forename: J
authors.initials: J
authors.lastname: Bruhwyler
authors.forename: J
authors.initials: J
authors.lastname: Scuvée-Moreau
authors.forename: V
authors.initials: V
authors.lastname: Seutin
authors.forename: H
authors.initials: H
authors.lastname: Masset
authors.forename: J C
authors.initials: JC
authors.lastname: Van Heugen
authors.forename: A
authors.initials: A
authors.lastname: Dresse
authors.forename: C
authors.initials: C
authors.lastname: Lejeune
authors.forename: E
authors.initials: E
authors.lastname: Decamp
authors.forename: L
authors.initials: L
authors.lastname: Szente
authors.forename: J
authors.initials: J
authors.lastname: Szejtli
authors.forename: J F
authors.initials: JF
authors.lastname: Liégeois
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D001682:Biological Availability; D003505:Cyclodextrins / Q000008:administration & dosage*; D005473:Fluoxetine / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D008297:Male; D051379:Mice; D008875:Middle Aged; D011446:Prospective Studies; D011903:Raphe Nuclei / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*; D013550:Swimming; D047408:gamma-Cyclodextrins
chemical_list: D003505:Cyclodextrins; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors; D047408:gamma-Cyclodextrins; C036139:norfluoxetine; C023792:gamma-cyclodextrin